CORRIGENDUM

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial


1Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester; 2Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester; 3MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London; 4London School of Hygiene and Tropical Medicine, London; 5UCL Cancer Institute, London; 6Guy’s and Saint Thomas’ NHS Foundation Trust, London; 7St James University Hospital, Leeds; 8Institute of Cancer Research, Sutton-London; 9Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham; 10Division of Cancer Sciences, The University of Manchester, Manchester; 11Katon West of Scotland Cancer Centre, University of Glasgow, Glasgow; 12The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool; 13Cardiff University, Cardiff; 14Faculty of Education Health and Wellbeing, University of Wolverhampton, Wolverhampton; 15RoyalMarsden NHS Foundation Trust, London; 16Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre, Glasgow; 17University of Sheffield, Sheffield; 18Kent Oncology Centre, Maidstone; 19Lancashire Teaching Hospitals NHS Foundation Trust, Preston; 20Worcestershire Acute Hospitals NHS Trust, Worcester; 21Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth; 22Queen’s Hospital, Romford; 23Torbay and South Devon NHS Foundation Trust, Torbay; 24Sussex Cancer Centre, Brighton; 25Department of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland; 26Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast; 27East Lancashire Hospitals NHS Trust, Blackburn; 28Oxford University Hospitals NHS Foundation Trust, Oxford; 29Shrewsbury and Telford Hospital NHS Trust, Shrewsbury; 30Yull and East Yorkshire Hospitals NHS Trust, Hull; 31Velindre Cancer Centre, Cardiff; 32Swansea University College of Medicine, Swansea; 33The Christie NHS Foundation Trust, Manchester; 34Heartlands Hospital, Birmingham; 35Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

The authors regret that Fig. 2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.

DOI of original article: https://doi.org/10.1093/annonc/mdz396

*Correspondence to: Prof. Noel W. Clarke, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Tel: +44 161 446 3364; Fax: +44 161 446 3365

E-mail: noel.clarke@christie.nhs.uk (N. W. Clarke).

0923-7534/© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).